Marriage Counselors in Wyncote, PA Accepting Medicare
6 Marriage Counselors found. Showing 1 - 6
 Khairiyyah Abdul-basit, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 604 Park Ln, Wyncote, PA 19095 Phone: 267-251-1487 |
 Dr. George A James Jr., PSY.D., LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 451 Greenwood Ave, Wyncote, PA 19095 Phone: 610-453-2333 |
Dr. Wendell H Scanterbury, PH.D. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 7750 Clements Rd, Wyncote, PA 19095 Phone: 347-244-4050 |
Saikia Moore, MS Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 25 Washington Ln Ste 6a, Wyncote, PA 19095 Phone: 215-586-3782 |
Jessica Paist, M.A. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 601 Summit Avenue, Wyncote, PA 19095 Phone: 215-380-0922 |
Dana Pierre-paul, MS MFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 25 Washington Ln Ste 6a21, Wyncote, PA 19095 Phone: 267-800-6589 |
News Archive
A new amyloid-targeting treatment for Alzheimer's disease
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
Health overhaul provisions raise moral, religious debates
The new health law has renewed concerns about some moral and religious issues, such as the government's role in providing sex education and health care workers' ability to opt out of providing end-of-life care and abortions.
Insufficient sleep may increase risk of teens engaging in unsafe sexual behaviors
Teenagers who don't get enough sleep may be at an increased risk of engaging in unsafe sexual behaviors, such as not using condoms or having sex under the influence of alcohol or drugs, according to new research published by the American Psychological Association.
BioSante to initiate two new LibiGel Phase III efficacy trials in FSD, HSDD
BioSante Pharmaceuticals, Inc., announced today that the Company plans to initiate two new LibiGel Phase III efficacy trials. This decision is based on an extensive analysis of previous efficacy data, consultation with key opinion leaders (KOLs) in female sexual dysfunction, testosterone therapy and placebo effects, as well as a meeting with the U.S. Food and Drug Administration (FDA).
Immunomedics product candidates, technologies receive recognition from QTDP program
Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.
› Verified 9 days ago
Pharmacists
Occupational Therapists
Psychologists
Counselors
Marriage Counselors
Dentists
Clinical Social Workers